Literature DB >> 6263180

Pharmacokinetics of mecillinam in health subjects.

J G Gambertoglio, S L Barriere, E T Lin, J E Conte.   

Abstract

Mecillinam is an amidino penicillinate derivative with a broad spectrum of activity against many gram-negative bacilli. Moreover, marked in vitro synergy against these organisms occurs when mecillinam is combined with other beta-lactam antibiotics. The purpose of this study was to determine the pharmacokinetic disposition of this antibiotic. A single dose of 10 mg/kg was administered to 12 healthy volunteers as a 15-min intravenous infusion. Multiple plasma and urine samples were collected at frequent intervals for 8 and 24 h, respectively. Plasma samples were assayed for mecillinam by using a specific high-pressure liquid chromatographic assay developed in our laboratory. Peak plasma levels ranged from 34 to 80 micrograms/ml, and after 4 h, plasma levels were 0.7 to 1.9 microgram/ml. The mean terminal plasma half-life was 51.1 +/- 8.6 min. The mean steady-state volume of distribution was calculated to be 0.23 +/- 0.04 liter/kg. The mean plasma and renal clearances were 3.5 +/- 0.4 and 2.5 +/- 0.4 ml/min per kg, respectively. The mean percentage of the dose excreted unchanged in the urine at 4 h was 67 +/- 5%; 71 +/- 6% was recovered in 24 h. Urine concentrations at 4 h were far above the minimum inhibitory concentration for susceptible gram-negative organisms.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6263180      PMCID: PMC352996          DOI: 10.1128/AAC.18.6.952

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Bacteriology and pharmacokinetics of the new amidino penicillin-mecillinam.

Authors:  J D Williams; J Andrews; M Mitchard; M J Kendall
Journal:  J Antimicrob Chemother       Date:  1976-03       Impact factor: 5.790

2.  Mecillinam serum levels following intravenous injection: a comparison with pivmecillinam.

Authors:  M Mitchard; J Andrews; M J Kendall; R Wise
Journal:  J Antimicrob Chemother       Date:  1977-07       Impact factor: 5.790

3.  Pharmacokinetic studies with mecillinam and pivmecillinam.

Authors:  K Roholt
Journal:  J Antimicrob Chemother       Date:  1977-07       Impact factor: 5.790

4.  Pharmacokinetics of pivmecillinam.

Authors:  R L Parsons; G A Hossack; G M Paddock
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

5.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

6.  Synergy of mecillinam (FL1060) with penicillins and cephalosporins against Proteus and Klebsiella, with observations on combinations with other antibiotics and against other bacterial species.

Authors:  R S Baltimore; J O Klein; C Wilcox; M Finland
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

7.  Pharmacokinetic studies with mecillinam and pivmecillinam.

Authors:  K Roholt; B Nielsen
Journal:  Chemotherapy       Date:  1975       Impact factor: 2.544

  7 in total
  8 in total

1.  The pharmacokinetics of mecillinam and pivmecillinam in pregnant and non-pregnant women.

Authors:  A Heikkilä; K Pyykkö; R Erkkola; E Iisalo
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

2.  Amdinocillin (Mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli.

Authors:  Elisabeth Thulin; Martin Sundqvist; Dan I Andersson
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

3.  Method of evaluating effects of antibiotics on bacterial biofilm.

Authors:  B L Prosser; D Taylor; B A Dix; R Cleeland
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

4.  Pharmacokinetics of bacmecillinam and pivmecillinam in volunteers.

Authors:  K Josefsson; T Bergan; L Magni; B G Pring; D Westerlund
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Pharmacokinetics of intravenous amdinocillin in healthy subjects and patients with renal insufficiency.

Authors:  I H Patel; L D Bornemann; V M Brocks; L S Fang; N E Tolkoff-Rubin; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

6.  Multiple-dose pharmacokinetics of amdinocillin in healthy volunteers.

Authors:  S L Barriere; J G Gambertoglio; E T Lin; J E Conte
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

7.  Pharmacokinetics of amdinocillin in healthy adults.

Authors:  B R Meyers; J Jacobson; J Masci; E Srulevitch; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

8.  Applications of minimal physiologically-based pharmacokinetic models.

Authors:  Yanguang Cao; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-23       Impact factor: 2.745

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.